These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 15141019)

  • 21. Preclinical pharmacology of bizelesin, a potent bifunctional analog of the DNA-binding antibiotic CC-1065.
    Walker DL; Reid JM; Ames MM
    Cancer Chemother Pharmacol; 1994; 34(4):317-22. PubMed ID: 8033298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single chemical modifications of the C-1027 enediyne core, a radiomimetic antitumor drug, affect both drug potency and the role of ataxia-telangiectasia mutated in cellular responses to DNA double-strand breaks.
    Kennedy DR; Gawron LS; Ju J; Liu W; Shen B; Beerman TA
    Cancer Res; 2007 Jan; 67(2):773-81. PubMed ID: 17234789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The A/T-specific DNA alkylating agent adozelesin inhibits Plasmodium falciparum growth in vitro and protects mice against Plasmodium chabaudi adami infection.
    Yanow SK; Purcell LA; Spithill TW
    Mol Biochem Parasitol; 2006 Jul; 148(1):52-9. PubMed ID: 16597469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutation spectra induced by adozelesin in the supF gene of human XP-A fibroblasts.
    Lee SY; Pfeifer GP; Lee CS
    Arch Pharm Res; 2010 Apr; 33(4):633-6. PubMed ID: 20422374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic and additive combinations of several antitumor drugs and other agents with the potent alkylating agent adozelesin.
    Smith KS; Folz BA; Adams EG; Bhuyan BK
    Cancer Chemother Pharmacol; 1995; 35(6):471-82. PubMed ID: 7533669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of p21CIP1 as a determinant of SC-560 response in human HCT116 colon carcinoma cells.
    Lee E; Choi MK; Han IO; Lim SJ
    Exp Mol Med; 2006 Jun; 38(3):325-31. PubMed ID: 16819292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.
    Chen Z; Xiao Z; Gu WZ; Xue J; Bui MH; Kovar P; Li G; Wang G; Tao ZF; Tong Y; Lin NH; Sham HL; Wang JY; Sowin TJ; Rosenberg SH; Zhang H
    Int J Cancer; 2006 Dec; 119(12):2784-94. PubMed ID: 17019715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies.
    Schwartz GH; Patnaik A; Hammond LA; Rizzo J; Berg K; Von Hoff DD; Rowinsky EK
    Ann Oncol; 2003 May; 14(5):775-82. PubMed ID: 12702533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175.
    Hayward RL; Schornagel QC; Tente R; Macpherson JS; Aird RE; Guichard S; Habtemariam A; Sadler P; Jodrell DI
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):577-83. PubMed ID: 15726367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does the antitumor cyclopropylpyrroloindole antibiotic CC-1065 cross-link DNA in tumor cells?
    Skladanowski A; Koba M; Konopa J
    Biochem Pharmacol; 2001 Jan; 61(1):67-72. PubMed ID: 11137711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
    He Y; Kaina B
    Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30925722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro evaluation of the novel chemotherapeutic agents U-73,975, U-77,779, and U-80,244 in gynecologic cancer cell lines.
    Hightower RD; Sevin BU; Perras J; Nguyen H; Angioli R; Untch M; Averette H
    Cancer Invest; 1993; 11(3):276-82. PubMed ID: 8485650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The antitumor enediyne C-1027 alters cell cycle progression and induces chromosomal aberrations and telomere dysfunction.
    McHugh MM; Gawron LS; Matsui S; Beerman TA
    Cancer Res; 2005 Jun; 65(12):5344-51. PubMed ID: 15958582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose- and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells.
    Lüpertz R; Wätjen W; Kahl R; Chovolou Y
    Toxicology; 2010 May; 271(3):115-21. PubMed ID: 20346999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the antineoplastic activity of adozelesin alone and in combination with 5-aza-2'-deoxycytidine and cytosine arabinoside on DLD-1 human colon carcinoma cells.
    Côté S; Momparler RL
    Anticancer Drugs; 1993 Jun; 4(3):327-33. PubMed ID: 7689364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel isothiacalothrixin B analogues exhibit cytotoxic activity on human colon cancer cells in vitro by inducing irreversible DNA damage.
    Dhatchana Moorthy N; Muthu Ramalingam B; Iqbal S; Mohanakrishnan AK; Gunasekaran K; Vellaichamy E
    PLoS One; 2018; 13(9):e0202903. PubMed ID: 30188913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The novel anthraquinone derivative IMP1338 induces death of human cancer cells by p53-independent S and G2/M cell cycle arrest.
    Choi HK; Ryu H; Son AR; Seo B; Hwang SG; Song JY; Ahn J
    Biomed Pharmacother; 2016 Apr; 79():308-14. PubMed ID: 27044842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topoisomerase poisons differentially activate DNA damage checkpoints through ataxia-telangiectasia mutated-dependent and -independent mechanisms.
    Siu WY; Lau A; Arooz T; Chow JP; Ho HT; Poon RY
    Mol Cancer Ther; 2004 May; 3(5):621-32. PubMed ID: 15141020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints.
    Sabisz M; Wesierska-Gadek J; Skladanowski A
    Biochem Pharmacol; 2010 May; 79(10):1387-97. PubMed ID: 20067769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of sequence-specific antitumor alkylating agent DNA damage from cells treated in culture and from a patient.
    Bubley GJ; Ogata GK; Dupuis NP; Teicher BA
    Cancer Res; 1994 Dec; 54(24):6325-9. PubMed ID: 7987822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.